Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01643161 · ClinicalTrials.gov registry record · NA
Guided Self-Help for Functional Neurological Symptoms
A NA study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- NA
- Development phase
- 33
- Enrollment target
NCT01643161: Clinical Trial NA study, sponsored by Mayo Clinic.
NCT01643161 is a NA study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 33 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01643161, a NA study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
Study Summary
Functional (psychogenic or somatoform) symptoms are commonly observed in neurology clinics. There is no known empirically validated treatment approach to functional symptoms. Cognitive Behavioral Therapy (CBT) can be effective, but there are major obstacles to its provision. The investigators will test the hypothesis that adding a CBT-based guided self-help (GSH) as compared to treatment as usual (TAU) improves patient outcomes.
Primary Outcome
Clinical Global Improvement scale score (much worse, worse, same, better, much better) rated by the patient.
Interventions
- BEHAVIORAL Treatment As Usual
- BEHAVIORAL Guided Self-Help
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2012-04 |
| Est. Completion | 2013-08 |
| Phase | NA |
Why NCT01643161 stopped before completion
NCT01643161 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Treatment As Usual is the first listed.
NCT01643161 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01643161 about?
NCT01643161 is a clinical study titled "Guided Self-Help for Functional Neurological Symptoms". Functional (psychogenic or somatoform) symptoms are commonly observed in neurology clinics. There is no known empirically validated treatment approach to functional symptoms. Cognitive Behavioral Therapy (CBT) can be effective, but there are major obstacles to its provision. The investigators will t...
What is the current status of trial NCT01643161?
This trial is currently terminated. It is a NA study. The enrollment target is 33 participants. The study started on 2012-04. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01643161?
The interventions under investigation include: Treatment As Usual (BEHAVIORAL), Guided Self-Help (BEHAVIORAL).
Who is sponsoring clinical trial NCT01643161?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01643161's enrollment target sits among peer trials
33 1574th of 2000 higher than 423 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia